{{ variable.name }} : {{ variable.values[selectedVariantsIndex[variable_index]].name }}
Quantity:
Cagrilintide is a long-acting synthetic analog of amylin, a natural pancreatic hormone involved in regulating appetite and energy balance. Developed by Novo Nordisk, it is studied primarily for chronic weight management and type 2 diabetes.
How It Works
• Amylin Mimetic: Cagrilintide activates amylin receptors in the brain to increase feelings of fullness (satiety).
• Delayed Gastric Emptying: It slows down how fast food leaves the stomach, helping reduce overall calorie intake.
• Glucagon Suppression: It helps suppress glucagon secretion to assist with blood sugar regulation.
• Once-Weekly Dosing: It is administered subcutaneously (under the skin) as a once-weekly injection.
CagriSema (Combination Therapy)
Cagrilintide's primary development focus is a fixed-dose combination with the GLP-1 receptor agonist semaglutide, known as CagriSema (combining cagrilintide 2.4 mg and semaglutide 2.4 mg).
• Complementary Pathways: While semaglutide acts on GLP-1 receptors in the gut and brain, cagrilintide acts on independent amylin/calcitonin receptors.
• Enhanced Efficacy: Clinical trials, such as the REDEFINE phase 3 program, have shown that CagriSema produces substantially greater mean body weight reductions (around 22% to 25% or more over 68 weeks) than either drug used on its own.